TY - JOUR
T1 - Proton therapy for head and neck cancer
T2 - A 12-year, single-institution experience
AU - Gunn, G. Brandon
AU - Garden, Adam S.
AU - Ye, Rong
AU - Ausat, Noveen
AU - Dahlstrom, Kristina R.
AU - Morrison, William H.
AU - Fuller, C. David
AU - Phan, Jack
AU - Reddy, Jay P.
AU - Shah, Shalin J.
AU - Mayo, Lauren L.
AU - Chun, Stephen G.
AU - Chronowski, Gregory M.
AU - Moreno, Amy C.
AU - Myers, Jeffery N.
AU - Hanna, Ehab Y.
AU - Esmaeli, Bita
AU - Gillison, Maura L.
AU - Ferrarotto, Renata
AU - Hutcheson, Katherine A.
AU - Chambers, Mark S.
AU - Ginsberg, Lawrence E.
AU - El-Naggar, Adel K.
AU - Rosenthal, David I.
AU - Zhu, Xiaorong Ronald
AU - Frank, Steven J.
N1 - Publisher Copyright:
© Copyright 2020 The Author(s).
PY - 2021/6/1
Y1 - 2021/6/1
N2 - Purpose: To characterize our experience and the disease control and toxicity of proton therapy (PT) for patients with head and neck cancer (HNC). Patients and Methods: Clinical outcomes for patients with HNC treated with PT at our institution were prospectively collected in 2 institutional review board-approved prospective studies. Descriptive statistics were used to summarize patient characteristics and outcomes. Overall survival, local-regional control, and disease-free survival were estimated by the Kaplan-Meier method. Treatment-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events (version 4.03) scale. Results: The cohort consisted of 573 patients treated from February 2006 to June 2018. Median patient age was 61 years. Oropharynx (33.3%; n = 191), paranasal sinus (11%; n = 63), and periorbital tissues (11%; n = 62) were the most common primary sites. Patients with T3/T4 or recurrent disease comprised 46% (n = 262) of the cohort. The intent of PT was definitive in 53% (n = 303), postoperative in 37% (n = 211), and reirradiation in 10% (n = 59). Median dose was 66 Gy (radiobiological equivalent). Regarding systemic therapy, 43% had received concurrent (n = 244), 3% induction (n = 19), and 15% (n = 86) had both. At a median follow-up of 2.4 years, 88 patients (15%) had died and 127 (22%) developed disease recurrence. The overall survival, local-regional control, and disease-free survival at 2 and 5 years were, respectively, 87% and 75%, 87% and 78%, and 74% and 63%. Maximum toxicity (acute or late) was grade 3 in 293 patients (51%), grade 2 in 234 patients (41%), and grade 1 in 31 patients (5%). There were 381 acute grade 3 and 190 late grade 3 unique toxicities across 212 (37%) and 150 (26%) patients, respectively. There were 3 late-grade 4 events across 2 patients (0.3%), 2 (0.3%) acute-grade 5, and no (0%) late-grade 5 events. Conclusions: The overall results from this prospective study of our initial decade of experience with PT for HNC show favorable disease control and toxicity outcomes in a multidisease-site cohort and provide a reference benchmark for future comparison and study.
AB - Purpose: To characterize our experience and the disease control and toxicity of proton therapy (PT) for patients with head and neck cancer (HNC). Patients and Methods: Clinical outcomes for patients with HNC treated with PT at our institution were prospectively collected in 2 institutional review board-approved prospective studies. Descriptive statistics were used to summarize patient characteristics and outcomes. Overall survival, local-regional control, and disease-free survival were estimated by the Kaplan-Meier method. Treatment-related toxicities were recorded according to the Common Terminology Criteria for Adverse Events (version 4.03) scale. Results: The cohort consisted of 573 patients treated from February 2006 to June 2018. Median patient age was 61 years. Oropharynx (33.3%; n = 191), paranasal sinus (11%; n = 63), and periorbital tissues (11%; n = 62) were the most common primary sites. Patients with T3/T4 or recurrent disease comprised 46% (n = 262) of the cohort. The intent of PT was definitive in 53% (n = 303), postoperative in 37% (n = 211), and reirradiation in 10% (n = 59). Median dose was 66 Gy (radiobiological equivalent). Regarding systemic therapy, 43% had received concurrent (n = 244), 3% induction (n = 19), and 15% (n = 86) had both. At a median follow-up of 2.4 years, 88 patients (15%) had died and 127 (22%) developed disease recurrence. The overall survival, local-regional control, and disease-free survival at 2 and 5 years were, respectively, 87% and 75%, 87% and 78%, and 74% and 63%. Maximum toxicity (acute or late) was grade 3 in 293 patients (51%), grade 2 in 234 patients (41%), and grade 1 in 31 patients (5%). There were 381 acute grade 3 and 190 late grade 3 unique toxicities across 212 (37%) and 150 (26%) patients, respectively. There were 3 late-grade 4 events across 2 patients (0.3%), 2 (0.3%) acute-grade 5, and no (0%) late-grade 5 events. Conclusions: The overall results from this prospective study of our initial decade of experience with PT for HNC show favorable disease control and toxicity outcomes in a multidisease-site cohort and provide a reference benchmark for future comparison and study.
KW - Head and neck cancer
KW - Proton therapy
KW - Survival
KW - Toxicity
UR - http://www.scopus.com/inward/record.url?scp=85110258882&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110258882&partnerID=8YFLogxK
U2 - 10.14338/IJPT-20-00065.1
DO - 10.14338/IJPT-20-00065.1
M3 - Article
AN - SCOPUS:85110258882
SN - 2331-5180
VL - 8
SP - 108
EP - 118
JO - International Journal of Particle Therapy
JF - International Journal of Particle Therapy
IS - 1
ER -